Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Incyte Corporation
The US FDA approved the JAK inhibitor momelotinib for myelofibrosis with anemia, with an analyst forecasting peak sales of more than $425m.
Plus deals involving Kelun Biotech, Pierre Fabre/Vertical, Novo Nordisk/Broad Institute, ABL Bio/Synaffix, Kriya/Tramontane, Palisade/Giiant and more.
CMS has not disclosed how many requests for the exception it received but will follow up with applicants regarding its decisions this month.
While biotech layoffs and big pharma restructuring dominate the news in 2023, the sector’s job market remains buoyant.
Drug Discovery Tools
- Drug Discovery Tools
- Other Names / Subsidiaries
- Maxia Pharmaceuticals, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.